KRAS and colorectal cancer: RAPTOR dysregulation was also implicated in a study of colorectal cancer: compared with cells that were either mutant or wild-type for both KRAS and PIK3CA, non-isogenic KRAS-mutant cells were reported to be relatively resistant to mTOR kinase inhibitor PP242, and to modestly overexpress RAPTOR [14].